title: Carmeda surface heparinization in neonatal ECMO systems: long-term experiments in a sheep model.
abstract: The thromboresistance in three Carmeda (Stockholm, Sweden) heparin-coated neonatal ECMO systems with a runtime of 45, 56 and 96 hours, respectively, and three noncoated systems with a runtime of 12, 42 and 66 hours, respectively, were compared using a sheep model. The flow rate was 200 ml/min and the activated clotting time (ACT) was kept at approximately 120 seconds. At the end of the experiment, the heparin-coated systems only contained minimal clotting while the controls showed major clotting in the entire system. Fibrin monomers were not detected until after 24 hours in the heparin-coated group, but demonstrated within 60 minutes in the noncoated group. It is concluded that the Carmeda heparin coating has a thromboresistant effect, and may be used to reduce the need for systemic heparinization in ECMO treatment of neonates.
authors.affiliation: Department of Pediatric Anesthesiology, St Göran's Hospital, Karolinska Institute, Stockholm, Sweden.
authors.forename: K
authors.initials: K
authors.lastname: Palmer
authors.forename: H
authors.initials: H
authors.lastname: Ehrén
authors.forename: R
authors.initials: R
authors.lastname: Benz
authors.forename: B
authors.initials: B
authors.lastname: Frenckner
mesh_terms: D000818:Animals; D015199:Extracorporeal Membrane Oxygenation / Q000009:adverse effects / Q000295:instrumentation*; D006400:Hematocrit; D006441:Hemoglobin A / Q000032:analysis; D006470:Hemorrhage / Q000517:prevention & control; D006493:Heparin / Q000008:administration & dosage* / Q000009:adverse effects; D012756:Sheep; D013927:Thrombosis / Q000517:prevention & control*
chemical_list: D006493:Heparin; D006441:Hemoglobin A